A GLP-1 dosage chart is useful only when the product, route, indication and patient population stay attached to each dose. Milligrams are not a universal measure of equivalent treatment strength across different medicines. A weekly injection dose also cannot be substituted for a daily tablet dose.
The tables below summarize selected current U.S. adult products, using prescribing information reviewed October 2, 2026. They are educational comparisons, not a personal titration, switching or restart plan. The list is not exhaustive: other diabetes products and presentations have their own labels.
Selected weekly injection doses for adults
| Product | Starting dose | Escalation framework | Maintenance or treatment doses | Adult maximum and important limits |
|---|---|---|---|---|
| Ozempic injection: semaglutide | 0.25 mg once weekly for four weeks | Increase to 0.5 mg; if additional glycemic control is needed, 1 mg after at least four weeks at 0.5 mg, then 2 mg after at least four weeks at 1 mg | 0.5, 1 or 2 mg weekly; the chronic kidney disease indication has a specific 1 mg maintenance instruction | 2 mg weekly; this row describes the injection label |
| Wegovy injection: semaglutide | 0.25 mg once weekly | Four-week steps through 0.5, 1 and 1.7 mg | Adult weight management: 1.7 or 2.4 mg weekly, with 2.4 mg recommended; selected adults may increase to 7.2 mg under label conditions | 7.2 mg applies only to selected adult weight-management use after tolerated 2.4 mg for at least four weeks and a clinical need for additional weight loss |
| Mounjaro: tirzepatide | 2.5 mg once weekly | If additional glycemic control is needed, increase in 2.5 mg steps after at least four weeks at the current dose | Treatment dose chosen for the labeled indication, response and tolerability | 15 mg weekly in adults; pediatric maximum differs |
| Zepbound: tirzepatide | 2.5 mg once weekly for four weeks, then 5 mg | Later increases in 2.5 mg steps after at least four weeks at the current dose | Weight management: 5, 10 or 15 mg weekly; adult obesity with obstructive sleep apnea: 10 or 15 mg weekly | 15 mg weekly; 2.5 mg is initiation, and 7.5 or 12.5 mg are not listed maintenance doses |
Sources: current Ozempic injection, Wegovy, Mounjaro and Zepbound labels. The chart does not authorize reaching a maximum or following an escalation without the prescribing plan.
Selected daily products for adults
| Product and route | Starting dose and progression | Adult maintenance or maximum | Administration distinction |
|---|---|---|---|
| Saxenda: liraglutide injection | 0.6 mg daily; weekly steps to 1.2, 1.8, 2.4 and 3 mg | Recommended adult dose is 3 mg daily; lower adult doses are for titration | Daily injection, rather than a weekly dose; tolerability and response reassessment are specified in the label |
| Wegovy: semaglutide tablets | 1.5 mg daily, then 4 mg, 9 mg and 25 mg in the label’s staged schedule | 25 mg daily maintenance | Morning fasting and water/waiting directions differ from injections |
| Foundayo: orforglipron tablets | 0.8 mg daily for at least 30 days; steps to 2.5 and 5.5 mg; optional later 9, 14.5 and 17.2 mg steps after at least 30 days each | Usual maximum 17.2 mg daily; maximum 9 mg with concomitant strong CYP3A4 inhibition | Whole tablet once daily, with or without food; additional interaction restrictions apply |
Sources: current Saxenda, Wegovy and Foundayo prescribing information. Tablet milligrams are not conversions from injection milligrams. Foundayo is not oral tirzepatide.
Starting, escalation, maintenance and maximum mean different things
A starting dose begins the product’s labeled treatment process. An escalation step is part of increasing the dose under the prescribing plan. A maintenance dose is a dose listed for ongoing treatment in the relevant indication. A maximum is a boundary, not a destination every patient should reach.
This distinction is especially important for Zepbound. Its 2.5 mg initiation dose is not an approved maintenance dose. Although 7.5 and 12.5 mg are available strengths, the label lists 5, 10 and 15 mg as weight-management maintenance doses. Available strength and maintenance recommendation are not synonymous.
Likewise, lower Saxenda adult doses are titration steps rather than interchangeable adult maintenance options. Its label includes instructions if 3 mg is not tolerated and a response reassessment at 16 weeks. That assessment belongs in clinical follow-up, not in a plan to force a dose through ongoing symptoms.
Our Zepbound dosage guide and semaglutide dosage guide provide further product context. Do not combine fragments from different guides into one custom schedule.
Wegovy 7.2 mg is not every Wegovy indication’s maximum
The June 2026 Wegovy label includes a conditional 7.2 mg weekly option for adult weight management. It requires prior tolerance of 2.4 mg for at least four weeks and a clinical indication for additional weight loss.
That option should not be copied into every Wegovy row. Adult cardiovascular-risk reduction uses its own maintenance instructions. Adult noncirrhotic MASH with specified fibrosis also has its own 2.4 mg regimen and tolerability provision. Pediatric weight-management instructions are separate and do not inherit the adult 7.2 mg option.
The route also matters. Wegovy tablets have a staged daily schedule ending at 25 mg maintenance; their number is not a weekly injection conversion. Confirm which product you were prescribed before reading the table.
For injection technique, see the Wegovy injection guide. Device use is a separate issue from whether a higher dose is appropriate.
Ozempic does not have a 2.4 mg injection dose
The current Ozempic injection label’s adult maximum is 2 mg once weekly. A 2.4 mg dose belongs to a different semaglutide product’s regimen; it is not an Ozempic escalation step.
The fact that Ozempic and Wegovy contain semaglutide does not make their pens, indications or schedules interchangeable. This chart’s Ozempic row also concerns injections, not a separately labeled tablet formulation.
Do not combine injections to approximate another brand’s chart number. An uncertain injection, missed dose or proposed switch needs the exact product’s instructions and the prescribing team’s advice. Our Ozempic dosage guide and Ozempic pen guide explain related product and presentation questions.
Mounjaro and Zepbound share an ingredient but differ in use
Both contain tirzepatide, but the brands have different labeled indications and treatment-dose instructions. Mounjaro’s glycemic-control escalation language should not be replaced with a weight-loss forecast. Zepbound has specific maintenance doses for weight management and for adult obesity with obstructive sleep apnea.
Their adult maximum of 15 mg weekly does not establish that every person should use it. Response, tolerance and the treatment indication matter. An earlier or lower dose is not “failing” simply because a higher strength exists.
The Mounjaro dosage guide gives further detail. If you are considering treatment, tirzepatide product information can help you ask about the exact formulation, eligibility and monitoring; it is not a brand-to-brand switching instruction.
Daily tablets need their own directions
Wegovy tablets are taken in the morning on an empty stomach with the label’s limited amount of water, followed by a waiting period before food, beverages or other oral medicines. They are swallowed whole, one tablet daily. Follow the current package and pharmacist’s instructions.
Foundayo tablets have different administration instructions and can be taken with or without food. Their maximum can be lower with a strong CYP3A4 inhibitor, and the label includes other combinations to avoid. A medication review is therefore part of interpreting the maximum-dose row.
Do not assume that all oral GLP-1 medicines need the same fasting routine. Our oral semaglutide versus injections guide explains why formulation and route need to be identified before comparing practical use.
Missed doses and longer gaps are product-specific
The weekly products do not all use the same missed-dose window. Ozempic injection instructions use a five-day window. Mounjaro and Zepbound use a four-day, 96-hour window, with separate rules about the interval between weekly doses.
A longer interruption can require a different restart process. The current Wegovy label directs reinitiation of escalation at a lower dosage after two or more consecutive missed weekly injections. Saxenda has a restart instruction after more than three days without a dose. Foundayo directs reinitiation of escalation at a lower dosage after seven or more missed daily doses.
These are separate labeled circumstances, not one class-wide restart rule. Use your exact product instructions and contact the prescriber if the gap, symptoms or previous dose make the next step unclear. Do not double a dose to compensate.
Our semaglutide missed-dose and restart guide provides questions for that review. A dose chart alone is not enough to decide how to resume after a prolonged gap.
Milligrams, milliliters and syringe units
Milligrams describe drug amount. Milliliters describe liquid volume. Syringe units describe markings on a particular syringe. They are not interchangeable quantities.
A compounded vial can have a concentration that differs from another vial or a branded presentation. A fixed number of units cannot be copied from one product to another without the actual concentration and prescription instructions.
Do not use this brand-dose chart to calculate a compounded injection volume. Our tirzepatide milligrams, milliliters and units guide explains the distinction. Ask the dispensing pharmacy to resolve any mismatch between your label, syringe and written instructions before using the product.
The FDA’s compounding guidance also distinguishes compounded preparations from FDA-approved products. A product page or familiar active ingredient does not make a custom formulation identical to a labeled brand.
Frequently asked questions
What is the highest GLP-1 dose?
There is no useful single class-wide number. Different ingredients, routes and indications have different regimens, and milligrams do not establish equivalent effects. Identify the exact product before asking about its maximum.
Should I increase every month until I reach the maximum?
Do not assume so. Labels have product-specific progression, indication and tolerability instructions. Your prescribing plan determines whether and when an increase is appropriate; ongoing symptoms need review.
Can I start Mounjaro at 7.5 mg because I used another medicine?
The current label starts Mounjaro at 2.5 mg weekly. Prior use of another medicine does not create a universal conversion authorizing a 7.5 mg start. Discuss the switch, treatment gap and symptoms with the clinician.
Are Ozempic 2 mg and Wegovy 2.4 mg equivalent?
They are different labeled product regimens. A chart does not establish equivalent benefit or permit combining injections. Use the exact prescription and product instructions.
Can I use this adult chart for a child or teenager?
No. Age-specific indications and limits differ. For example, Mounjaro’s current pediatric maximum differs from its adult maximum, and Wegovy’s adult 7.2 mg option does not apply to the pediatric regimen.
Is a tirzepatide dose below 2.5 mg a standard branded starting dose?
The reviewed U.S. Mounjaro and Zepbound injection labels start at 2.5 mg once weekly. Mounjaro uses that dose for initiation rather than glycemic control; Zepbound uses it for initiation rather than maintenance. A smaller amount is not the standard branded initiation schedule in those labels. If you have tolerability or treatment questions, contact the prescriber about the exact product and plan. Do not split a preset pen or convert milligrams into syringe units using another formulation’s concentration. Compounded formulations and their instructions require their own assessment and are not FDA-approved versions of the branded products. Mounjaro Label. Zepbound Label.
Where should I start if I am exploring treatment?
Read our GLP-1 overview and discuss your diagnosis, goals, medicines and follow-up with a clinician. Semaglutide product information can help prepare that conversation, but a chart is not a prescription or an eligibility assessment.
Educational information for adults; individual treatment decisions require a qualified clinician. Sources reviewed October 2, 2026. Original AI-generated article images depict fictional people and objects, not patient outcomes. Other editorial images are illustrative. Graphics summarize the cited sources.
